Cargando…
Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis
Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998598/ https://www.ncbi.nlm.nih.gov/pubmed/33799578 http://dx.doi.org/10.3390/biomedicines9030285 |
_version_ | 1783670588781363200 |
---|---|
author | Agarkova, Alina Pokrovskii, Mikhail Kolesnichenko, Pavel Gureev, Vladimir Gudyrev, Oleg Peresypkina, Anna Soldatov, Vladislav Nesterov, Arkadii Denisyuk, Tatyana Korokin, Mikhail |
author_facet | Agarkova, Alina Pokrovskii, Mikhail Kolesnichenko, Pavel Gureev, Vladimir Gudyrev, Oleg Peresypkina, Anna Soldatov, Vladislav Nesterov, Arkadii Denisyuk, Tatyana Korokin, Mikhail |
author_sort | Agarkova, Alina |
collection | PubMed |
description | Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 × 10(9) CFU/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p < 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p < 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase—17%, superoxide dismutase—34%, malondialdehyde and acetylhydroperoxides—50%, and nitric oxide—85% (p < 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM. |
format | Online Article Text |
id | pubmed-7998598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79985982021-03-28 Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis Agarkova, Alina Pokrovskii, Mikhail Kolesnichenko, Pavel Gureev, Vladimir Gudyrev, Oleg Peresypkina, Anna Soldatov, Vladislav Nesterov, Arkadii Denisyuk, Tatyana Korokin, Mikhail Biomedicines Article Purulent meningitis (PM) is a severe disease, characterized by high mortality and a formation of a residual neurological deficit. Loss of treatment of PM leads to the lethal outcome in 100% of cases. In addition, death and the development of residual neurological complications are possible despite adequate therapy. The aim of the study was to evaluate the cerebroprotective effects of a new pharmacological compound 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid (EMHDPA) on the bacterial purulent meningitis in a model of experimental pneumococcal meningitis. Meningitis was simulated by intrathecal injection of the suspension containing Streptococcus pneumoniae at the concentration of 5 × 10(9) CFU/mL. The cerebroprotective effect was evaluated by survival rates, the severity of neurological deficit, investigatory behaviors, and results of short-term and long-term memory tests. The group administered with EMHDPA showed high survival rates, 80%. Animals treated with the studied compound showed a higher clinical assessment of the rat health status and specific force, and a lesser intensity of neurological deficit compared to the control group (p < 0.05). Locomotor activity of the animals treated with EMHDPA was significantly higher compared to the control group (p < 0.05). There is a decrease in the activity of all estimated indicators of oxidative stress in the group administered with 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid relative to the control group: a decrease in the activity of catalase—17%, superoxide dismutase—34%, malondialdehyde and acetylhydroperoxides—50%, and nitric oxide—85% (p < 0.05). Analysis of the data obtained during the experiment leads to the conclusion about the effectiveness of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of the experimental PM. MDPI 2021-03-11 /pmc/articles/PMC7998598/ /pubmed/33799578 http://dx.doi.org/10.3390/biomedicines9030285 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Agarkova, Alina Pokrovskii, Mikhail Kolesnichenko, Pavel Gureev, Vladimir Gudyrev, Oleg Peresypkina, Anna Soldatov, Vladislav Nesterov, Arkadii Denisyuk, Tatyana Korokin, Mikhail Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title | Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title_full | Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title_fullStr | Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title_full_unstemmed | Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title_short | Cerebroprotective Effects of 2-Ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic Acid in the Treatment of Purulent Meningitis |
title_sort | cerebroprotective effects of 2-ethyl-6-methyl-3-hydroxypyridine-2,6-dichlorophenyl(amino)phenylethanoic acid in the treatment of purulent meningitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998598/ https://www.ncbi.nlm.nih.gov/pubmed/33799578 http://dx.doi.org/10.3390/biomedicines9030285 |
work_keys_str_mv | AT agarkovaalina cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT pokrovskiimikhail cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT kolesnichenkopavel cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT gureevvladimir cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT gudyrevoleg cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT peresypkinaanna cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT soldatovvladislav cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT nesterovarkadii cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT denisyuktatyana cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis AT korokinmikhail cerebroprotectiveeffectsof2ethyl6methyl3hydroxypyridine26dichlorophenylaminophenylethanoicacidinthetreatmentofpurulentmeningitis |